Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.
Yildirim ME, Karadurmuş N, Ökten İN, Türk HM, Urakçı Z, Arslan Ç, Çelik S, Dane F, Şendur MAN, Bilir C, Karabulut B, Cicin İ, Çubukçu E, Karaca M, Ozcelik M, Artaç M, Tanrikulu E, Alacacioglu A, Açıkgöz Ö, Öven B, Geredeli Ç, Çil T, Harputluoğlu H, Kefeli U, Bozkurt O, Tural D, Sakin A, Yalçın Ş, Gumus M. Yildirim ME, et al. Among authors: acikgoz o. J Oncol Pharm Pract. 2024 Apr 13:10781552241241004. doi: 10.1177/10781552241241004. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 38613329
Netrin-1 in cancer: Potential biomarker and therapeutic target?
Kefeli U, Ucuncu Kefeli A, Cabuk D, Isik U, Sonkaya A, Acikgoz O, Ozden E, Uygun K. Kefeli U, et al. Among authors: acikgoz o. Tumour Biol. 2017 Apr;39(4):1010428317698388. doi: 10.1177/1010428317698388. Tumour Biol. 2017. PMID: 28443497 Free article. Review.
The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study.
Akdeniz N, Kaplan MA, Uncu D, İnanç M, Kaya S, Dane F, Küçüköner M, Demirci A, Bilici M, Durnalı AG, Koral L, Şendur MAN, Erol C, Türkmen E, Ölmez ÖF, Açıkgöz Ö, Laçin Ş, Şahinli H, Urakçı Z, Işıkdoğan A. Akdeniz N, et al. Among authors: acikgoz o. Int J Colorectal Dis. 2021 Jun;36(6):1311-1319. doi: 10.1007/s00384-021-03888-9. Epub 2021 Feb 14. Int J Colorectal Dis. 2021. PMID: 33586012
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
Hizal M, Bilgin B, Paksoy N, Açıkgöz Ö, Sezer A, Gürbüz M, Ak N, Yücel Ş, Ayhan M, Erol C, Demirkıran A, Mandel NM, Shbair A, Gökmen İ, Başoğlu T, Paydaş S, Demiray AG, İriağaç Y, Şakalar T, Zeynelgil E, Tatlı AM, Bahçeci A, Güven DC, Caner B, Can A, Gülmez A, Karakaş Y, Yalçın B, Demirkazık A, Bilici A, Aydıner A, Yumuk PF, Şendur MAN. Hizal M, et al. Among authors: acikgoz o. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7. Epub 2021 Jul 31. J Cancer Res Clin Oncol. 2022. PMID: 34331582
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Bilici A, Uysal M, Menekse S, Akin S, Yildiz F, Turan M, Sezgin Goksu S, Beypinar I, Sakalar T, Değirmenci M, Erdem D, Basaran G, Olmez OF, Avci N, Tural D, Sakin A, Turker S, Demir A, Temiz S, Kaplan MA, Dogan M, Tanriverdi O, Bilgetekin I, Cinkir HY, Acikgoz O, Paydas S, Uslu R, Turhal S. Bilici A, et al. Among authors: acikgoz o. Cancer Invest. 2022 Feb;40(2):199-209. doi: 10.1080/07357907.2021.2017952. Epub 2021 Dec 22. Cancer Invest. 2022. PMID: 34894960
Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study.
Goktas Aydin S, Kavak EE, Topcu A, Bayramgil A, Akgul F, Kahraman S, Aykan MB, Altıntas YE, Helvaci K, Urun Y, Bilici A, Seker M, Sendur MAN, Olmez OF, Acikgoz O, Cicin I. Goktas Aydin S, et al. Among authors: acikgoz o. Biomol Biomed. 2023 Nov 3;23(6):1089-1095. doi: 10.17305/bb.2023.9253. Biomol Biomed. 2023. PMID: 37289436 Free PMC article.
86 results